Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREPARED: Ropinirole PR vs IR in Advanced PD
NCT00331149Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2006
- Primary completion
- Aug 2007
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of ropinirole in Parkinson's disease (PD) (2 arms), sponsored by GSK. Primary endpoint: Percentage of participants with at least a 20% maintained reduction in Baseline time spent 'off' at Week 24 LOCF. Started Jun 2006; status: completed.
02
Drugs
ropinirole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00331149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00331149.